Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of BioCentury, Week in Review: Clinical Results

BioCentury, Week in Review Current Issue
  • Bendamustine: Updated Phase III data

    InnoPharmax Inc. (GreTai-E:4172), Taipei, Taiwan SymBio Pharmaceuticals Ltd. (JASDAQ:4582), Tokyo, Japan Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Astellas Pharma Inc. (Tokyo:4503), Tokyo, …

    Published on 3/4/2013
  • Bydureon exenatide endocrine/metabolic data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Bydureon exenatide; Byetta exenatide; Januvia sitagliptin …

    Published on 3/4/2013
  • Cilengitide: Phase III data

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Cilengitide (Impetreve) (EMD 121974) (formerly NSC 707544) Business: Cancer Molecular target: Integrin alpha(V)beta(3) (CD51/CD61); Integrin alpha(V)beta(5) …

    Published on 3/4/2013
  • Dalbavancin: Phase III data

    Durata Therapeutics Inc. (NASDAQ:DRTX), Chicago, Ill. Product: Dalbavancin (RQ-00000002) Business: Infectious Molecular target: D-alanyl-D-alanine Description: Second-generation once-weekly glycopeptide antibiotic …

    Published on 3/4/2013
  • Daxas roflumilast: Postmarketing study data

    Forest Laboratories Inc. (NYSE:FRX), New York, N.Y. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Daxas roflumilast (Daliresp) (…

    Published on 3/4/2013
  • KB002: Phase I/II data

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO), South San Francisco, Calif. Product: KB002 Business: Inflammation Molecular target: Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116) …

    Published on 3/4/2013
  • Naloxegol: Phase III data

    Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Naloxegol (formerly NKTR-118) Business: Gastrointestinal Molecular target: Mu opioid receptor (OPRM1) (…

    Published on 3/4/2013
  • Omalizumab: Phase III data

    Genentech Inc., South San Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Omalizumab(Xolair) (RG3648) Business: Dermatology Molecular …

    Published on 3/4/2013
  • PAZ320: Additional Phase II data

    Boston Therapeutics Inc. (OTCBB:BTHE), Manchester, N.H. Product: PAZ320 Business: Endocrine/Metabolic Molecular target: NA Description: Chewable polysaccharide that blocks the action of carbohydrate-hydrolyzing enzymes …

    Published on 3/4/2013
  • Rencarex girentuximab: Additional Phase III data

    Wilex AG (Xetra:WL6), Munich, Germany Product: Rencarex girentuximab (formerly WX-G250) Business: Cancer Molecular target: Carbonic anhydrase IX (CAIX) Description: Chimeric mAb against carbonic anhydrase IX (CAIX) …

    Published on 3/4/2013
  • Tavaborole: Phase III data

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Product: Tavaborole (AN2690) Business: Infectious Molecular target: NA Description: Topical antifungal agent Indication: Treat onychomycosis Endpoint: …

    Published on 3/4/2013
  • ToleroMune cat allergy therapy: Additional Phase II data

    Circassia Ltd., Oxford, U.K. Product: ToleroMune cat allergy therapy, Cat-PAD Business: Inflammation Molecular target: NA Description: T cell vaccine using ToleroMune T cell epitope desensitization technology Indication…

    Published on 3/4/2013
  • VX-809: Additional Phase II data

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass. Product: VX-809 (Lumacaftor) Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (CFTR) Description: Small molecule …

    Published on 3/4/2013
  • Bavituximab: Updated Phase IIb data

    Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Tustin, Calif. Product: Bavituximab (3G4) Business: Cancer Molecular target: Phosphatidylserine Description: Chimeric mAb against phosphatidylserine Indication: Second-line …

    Published on 2/25/2013
  • Capesaris: Phase II data

    GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Capesaris (GTx-758) Business: Cancer Molecular target: Estrogen receptor alpha Description: Oral selective estrogen receptor alpha agonist Indication: Treat advanced …

    Published on 2/25/2013
  • Capesaris: Phase II data

    GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Product: Capesaris (GTx-758) Business: Cancer Molecular target: Estrogen receptor alpha Description: Oral selective estrogen receptor alpha agonist Indication: Treat metastatic …

    Published on 2/25/2013
  • Cogane: Phase II data

    Phytopharm plc (LSE:PYM), Godmanchester, U.K. Product: Cogane (PYM50028) Business: Neurology Molecular target: Glial cell-derived neurotrophic factor (GDNF) Description: Synthetic, orally-active neurotrophic factor …

    Published on 2/25/2013
  • ConfirmMDx for Prostate Cancer diagnostic data

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Product: ConfirmMDx for Prostate Cancer Business: Diagnostic Molecular target: NA Description: Prostate cancer diagnostic based on DNA methylation biomarkers Indication: …

    Published on 2/25/2013
  • Elaprase idursulfase: Phase I/II data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Elaprase idursulfase (HGT2310) Business: Endocrine/Metabolic Molecular target: Not applicable Description: Iduronate-2-sulfatase enzyme Indication: Treat …

    Published on 2/25/2013
  • Eliglustat tartrate: Additional Phase III data

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Eliglustat tartrate (formerly Genz-112638) Business: Endocrine/Metabolic Molecular target: Glucosylceramide synthase (GCS) Description: Ceramide analog that …

    Published on 2/25/2013
  • Eliglustat tartrate: Additional Phase III data

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Eliglustat tartrate (formerly Genz-112638) Business: Endocrine/Metabolic Molecular target: Glucosylceramide synthase (GCS) Description: Ceramide analog that …

    Published on 2/25/2013
  • HGT1410: Phase I/II data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: HGT1410 Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human heparan N-sulfatase Indication: Treat mucopolysaccharidosis IIIA (MPS …

    Published on 2/25/2013
  • Impracor neurology data

    Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY), Solana Beach, Calif. Product: Impracor (TDLP-110) (formerly Ketotransdel) Business: Neurology Molecular target: NA Description: Topical cream formulation of 10% ketoprofen, a…

    Published on 2/25/2013
  • ITI-214: Phase I data

    Intra-Cellular Therapies Inc., New York, N.Y. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: ITI-214 Business: Neurology Molecular target: Phosphodiesterase-1 (PDE-1) Description: Phosphodiesterase-1…

    Published on 2/25/2013
  • Kuvan: Phase III data

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Kuvan (6R-BH4) sapropterin dihydrochloride …

    Published on 2/25/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?